Loading…
Loading…
NovAccess Global (OTCMKTS:XSNX - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk. Analyst Ratings This is a summary of
Roivant Sciences (NASDAQ: ROIV - Get Free Report) and NovAccess Global (OTCMKTS:XSNX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of current
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company expects to reschedule the annual meeting shortly.
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company's immunotherapy platform. The license pertains to the use of Isocitrate Dehydrogenase-1 (IDH1), a protein previously known to impact cell metabolism.
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7 million financing transaction with Sumner Global LLC remains pending, as Sumner Global has not yet obtained the funding necessary to close the transaction.
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced it entered into a securities purchase agreement with an affiliate of Sumner Global LLC ("Sumner") for a total financing of $10.7 million. Pursuant to the agreement, Sumner agreed to purchase 33.0 million newly issued shares of the Company's unregistered common stock at $0.11 per share, for a $3.63 million cash investment payable on or before January 31, 2024, subject to a financing contingency.
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th Investor Summit Presentation: December 7th, 2023 @ 1:30 PM ET Location: https://us06web.zoom.us/webinar/register/WN_ps0tLsybTUyu5q9_J_OXYA 1x1s will be available for qualified investors The conference is completely complimentary to qualified investors About NovAccess Global NovAccess Global is a preclinical, IND-ready biomedical company accelerating novel cancer diagnostics and therapeutics.
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board.